Elevation Oncology: Continuing To Seek Footing As It Climbs (Rating Upgrade) [Seeking Alpha]
Elevation Oncology, Inc. - Common stock (ELEV)
Company Research
Source: Seeking Alpha
Their flagship project, EO-3021, is a phase 1 study targeting Claudin-18.2 and has shown promising early results. Elevation Oncology is also exploring anti-HER3 ADCs and is close to nominating a candidate for clinical development in this area. Topline Summary and Update Elevation Oncology, Inc. NASDAQ: ELEV ) has had a banner year so far for a small-cap biotech, coming out of a long, long holding period with the shelving of their once-promising seribantumab program and beginning Recommended For You Recommended For You
Show less
Read more
Impact Snapshot
Event Time:
ELEV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ELEV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ELEV alerts
High impacting Elevation Oncology, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ELEV
News
- Elevation Oncology: Mid-2024 EO-3021 Data Could Get Ball Rolling [Seeking Alpha]Seeking Alpha
- Elevation Oncology, Inc. (NASDAQ: ELEV) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $8.00 price target on the stock.MarketBeat
- Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements [Yahoo! Finance]Yahoo! Finance
- Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business AchievementsPR Newswire
- Elevation Oncology, Inc. (NASDAQ: ELEV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.MarketBeat
ELEV
Sec Filings
- 5/2/24 - Form S-3
- 5/2/24 - Form 8-K
- 5/2/24 - Form 10-Q
- ELEV's page on the SEC website